Paper Details

  1. Home
  2. Paper Details

Additive effects of salmeterol and fluticasone or theophylline in COPD.

Author: CalderaroF, CazzolaM, CentanniS, Di LorenzoG, Di PernaF, TestiR

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Fluticasone propionate and salmeterol given together were more effective than salmeterol alone in improving lung function in patients with COPD. A randomized controlled trial involving 80 patients found that both treatments significantly improved lung function, with the combination therapy showing greater improvements than salmeterol alone. Furthermore, the combination therapy resulted in a greater improvement in lung function after salbutamol, suggesting a synergistic effect.
Paper Details　
Original Abstract of the Article :
BACKGROUND: ss(2)-Agonists and corticosteroids or theophylline can interact to produce beneficial effects on airway function in asthma, but this has not been established in COPD. METHODS: Eighty patients with well-controlled COPD were randomized to receive 3 months of treatment in one of four treat...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1378/chest.118.6.1576

データ提供：米国国立医学図書館（NLM）

Combining Therapies for COPD: A Multi-faceted Approach to Lung Health

Chronic obstructive pulmonary disease (COPD), a debilitating respiratory condition, is like a dense fog that obscures lung function and hinders a person's ability to breathe freely. This research, like a team of doctors working together to clear the fog, investigates the additive effects of different therapies for COPD, seeking to improve lung function and enhance patient well-being.

A Multi-faceted Approach to COPD Treatment

The study's findings are like finding a series of hidden pathways through the fog of COPD, revealing that combining different therapies can lead to significant improvements in lung function. The research demonstrates that combining salmeterol, a long-acting beta2-agonist, with fluticasone propionate, an inhaled corticosteroid, results in greater improvements in lung function compared to using salmeterol alone. This discovery is like finding a more efficient and effective route through the fog, leading to a clearer and healthier breathing experience for COPD patients.

Improving Lung Function and Quality of Life for COPD Patients

This research underscores the importance of a multi-faceted approach to COPD treatment. By combining different therapies, like weaving together different threads to create a stronger fabric, clinicians can improve lung function and enhance the quality of life for COPD patients. This research serves as a guide for clinicians, helping them to navigate the fog of COPD and provide optimal care for their patients.

Dr.Camel's Conclusion

This study is a reminder that even in the fog of chronic illness, there are ways to find clearer pathways to better health. Combining different therapies for COPD, like a skilled camel caravan navigating a challenging terrain, can improve lung function and enhance the quality of life for patients. This research highlights the importance of seeking a multi-faceted approach to treatment, allowing us to clear the fog of disease and pave the way for a healthier future.

Date :
  1. Date Completed 2001-01-18
  2. Date Revised 2019-05-14
Further Info :

Pubmed ID

11115442

DOI: Digital Object Identifier

10.1378/chest.118.6.1576

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.